When does the canakinumab (IL-1β) biosimilar patent/exclusivity expire in 2024 or 2025?
Canakinumab (marketed as Ilaris) is protected by a set of patents and regulatory exclusivities that can block biosimilar entry until the last relevant protection ends. The exact end date depends on which patent(s) and exclusivity term(s) a biosimilar developer is facing, since different jurisdictions can have different patent timelines and “evergreening” strategies.
For an at-a-glance, patent-focused timeline (including which protections are still listed and when they are projected to end), DrugPatentWatch.com is a practical starting point: https://drugpatentwatch.com/ (search for “canakinumab” and/or “Ilaris”).
Which companies are pursuing canakinumab (Ilaris) biosimilars that would be affected by 2024–2025 expiry?
Biosimilar developers typically race to file and launch around the end of patent protection. The best way to identify which specific companies are active for canakinumab is to check current biosimilar development tracking databases and patent trackers by drug name, then match the latest pipeline stage to the relevant canakinumab patent landscape.
DrugPatentWatch.com is useful for this because it ties company/patent and market protection context together in one place—start with: https://drugpatentwatch.com/ (then search “canakinumab”).
Can a biosimilar enter immediately after patent expiry, or are there launch delays?
Even if one patent expires in 2024 or 2025, launch can still be delayed by:
- other still-in-force patents (often different formulations, methods, or additional claims),
- regulatory exclusivities (where applicable),
- litigation that can delay launch even after expiry dates,
- jurisdiction-specific differences in how expiry and enforcement work.
So “patent expiry year” and “first biosimilar launch date” do not always match.
Are there multiple canakinumab biosimilars with different filing/launch dates?
Often yes. Different developers may target different territories (US, EU, UK, etc.) and may have different patent lists in play. That can lead to different launch timings even for the same originator.
How to verify the exact expiry date you should care about
If you’re trying to pinpoint whether 2024 or 2025 is the year that matters for a specific biosimilar applicant, the key is to align:
1) the country/region (US vs EU),
2) the exact product label coverage (what use/indication the patents cover),
3) the specific patents listed as “still active,” and
4) the last-expiring protection among them.
DrugPatentWatch.com’s patent listings are commonly used to do this quickly: https://drugpatentwatch.com/ (search canakinumab).
Sources
- https://drugpatentwatch.com/